iRhythm to Buy Vital Connect in $287.5 Million Cardiac-Monitoring Deal
iRhythm said the acquisition would immediately widen its addressable market and push the company beyond ambulatory cardiac monitoring into a broader cardiac monitoring and intelligence platform.
iRhythm Holdings, Inc. (IRTC) agreed to acquire Vital Connect, Inc. in a mixed-consideration deal valued at approximately $287.5 million, extending its device portfolio beyond ambulatory ECG monitoring.
The transaction adds Vital Connect's mobile cardiac telemetry and multi-vitals monitoring technology to iRhythm's Zio platform, a combination the company said would expand its addressable market immediately upon closing rather than over a multiyear product cycle.
"This combination represents a significant next step in iRhythm's evolution from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform," said Quentin Blackford, President and Chief Executive Officer of iRhythm. The company has been building toward that platform ambition for several quarters, pointing on recent earnings calls to a technology license agreement with BioIntelliSense for multi-sensor capabilities and a partnership with Lucem Health on AI-driven arrhythmia detection, both aimed at extending Zio's reach beyond long-term continuous monitoring.
The deal lands as iRhythm's core business has been compounding at a rate that gives it room to fund bolt-on acquisitions without straining its balance sheet. Revenue rose 30.7% in the third quarter of 2025 and 25.7% in the first quarter of 2026, and the company entered 2026 with $549.6 million in unrestricted cash, cash equivalents and marketable securities, alongside its first full year of positive free cash flow in company history. That cash position gives iRhythm flexibility to pair the Vital Connect deal's mixed stock-and-cash structure with continued investment in its own pipeline, including the next-generation Zio MCT solution submitted to the FDA.
iRhythm's acquisition activity follows a pattern set by its technology partnerships over the past two years: rather than build multi-vitals and telemetry capability in-house, the company has increasingly licensed or acquired it, a strategy consistent with management's stated goal of becoming a broader monitoring and intelligence platform rather than a single-device manufacturer.
The deal is subject to customary closing conditions. The combined technology would deepen customer partnerships and accelerate growth by letting health systems consolidate cardiac telemetry and vitals monitoring within a single platform, an integration argument that echoes the company's recent push into primary care and value-based care channels.